Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, San Francisco, California.
Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, San Francisco, California.
Clin Gastroenterol Hepatol. 2022 Mar;20(3):701-703.e2. doi: 10.1016/j.cgh.2021.01.043. Epub 2021 Jan 29.
Among patients with hepatocellular carcinoma (HCC), elevated α-fetoprotein (AFP) has been shown to predict waitlist dropout, high-risk histopathologic features, and inferior post-liver transplant (LT) outcome. Nevertheless, many patients with HCC have a normal AFP and yet still experience waitlist dropout or post-LT recurrence. Because of the degree of imprecision associated with AFP, there is a quest for other biomarkers that may be complementary to or better than AFP in predicting prognosis in LT. Lectin-reactive AFP (AFP-L3) and des-gamma-carboxyprothrombin (DCP) are biomarkers that have been used in conjunction with AFP as HCC surveillance or diagnostic tools. However, the utility of these biomarkers in LT for HCC is not established.
在肝细胞癌（HCC）患者中，甲胎蛋白（AFP）升高已被证明可预测等待名单脱落、高危组织病理学特征和肝移植（LT）后较差的结果。然而，许多 HCC 患者 AFP 正常，但仍会出现等待名单脱落或 LT 后复发。由于 AFP 存在一定程度的不准确性，因此人们一直在寻找其他生物标志物，这些标志物可能在预测 LT 预后方面与 AFP 互补或优于 AFP。凝集素反应性 AFP（AFP-L3）和脱γ-羧基凝血酶原（DCP）是与 AFP 一起用于 HCC 监测或诊断工具的生物标志物。然而，这些生物标志物在 HCC LT 中的应用尚未确定。
